title: Role of leukotriene inhibitors in the postoperative management of nasal polyps.
abstract: This was a prospective double blind comparative study on 40 patients. It compared the effects of the leukotriene receptor antagonist montelukast and beclomethasone nasal spray on the post-operative course of patients with sinonasal polyps. All patients underwent endoscopic sphenoethmoidectomy and were randomized post-operatively into two groups. Group I: 20 patients (9 females and 11 males) age 17 to 67 (32.4 +/- 9.5 years), receiving 10 mg montelukast orally daily and Group II: 20 patients (6 females and 14 males) age 17 years to 57 years (33.5 +/- 11.9 years), receiving 400 ug beclomethasone local sprays daily. All patients were followed up for 1 year and a symptom score was recorded throughout this period. There was a significant reduction in symptom scores in both groups throughout the study period. In the montelukast group improvement was more marked in itching, post-nasal discharge and headache. The control of sneezing and rhinorrhea was comparable in both groups with a marginal advantage of montelukast. Steroids had a more marked effect on smell disturbances and obstruction. There was no difference in the recurrence rate or in the need for rescue medications between both groups. Both drugs seem to have a complementary action and further studies are needed to determine which patients should receive which treatment.
authors.affiliation: Departments of Otorhinolaryngology, Ain-Shams Universitiy, Cairo, Egypt. bemostafa@entainshams.com
authors.forename: Badr E
authors.initials: BE
authors.lastname: Mostafa
authors.forename: Hossam
authors.initials: H
authors.lastname: Abdel Hay
authors.forename: Hussam E
authors.initials: HE
authors.lastname: Mohammed
authors.forename: Mohammed
authors.initials: M
authors.lastname: Yamani
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001507:Beclomethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D003521:Cyclopropanes; D004311:Double-Blind Method; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006261:Headache / Q000517:prevention & control; D006801:Humans; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009298:Nasal Polyps / Q000601:surgery*; D000857:Olfaction Disorders / Q000517:prevention & control; D011182:Postoperative Care; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D011537:Pruritus / Q000517:prevention & control; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D012912:Sneezing / Q000187:drug effects; D013440:Sulfides
chemical_list: D000085:Acetates; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D005938:Glucocorticoids; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D001507:Beclomethasone; C093875:montelukast